Bulk Manufacturer of Controlled Substances Application: Research Triangle Institute, 5501 [2019-02881]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 35 / Thursday, February 21, 2019 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[OMB Number 1121–0296]
[Docket No. DEA–392]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested; Reinstatement,
With Change, of a Previously
Approved Collection for Which
Approval Has Expired: 2018 Census of
Medical Examiner and Coroner Offices
(CMEC)
Bulk Manufacturer of Controlled
Substances Application: Research
Triangle Institute
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 25, 2019. Such persons
may also file a written request for a
hearing on the application on or before
March 25, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
25, 2018, Research Triangle Institute,
3040 East Cornwallis Road, Hermann
Bldg., Room 106, Research Triangle
Park, North Carolina 27709, re-applied
to be registered as a bulk manufacturer
of small quantities of
Tetrahydrocannabinols (7370), a basic
class of a controlled substance listed in
schedule I.
The company will manufacture via
synthesis Tetrahydrocannabinols (7370),
for use by researchers as Active
Pharmaceutical Ingredients (API) for
clinical trials.
amozie on DSK3GDR082PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–02881 Filed 2–20–19; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
17:08 Feb 20, 2019
Jkt 247001
Department of Justice.
30-Day notice.
AGENCY:
ACTION:
The Department of Justice
(DOJ), Office of Justice Programs,
Bureau of Justice Statistics (BJS), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection
was previously published in the Federal
Register, Volume 83, Number 238, page
63909 on Wednesday, December 12,
2018. Following publication of the 60day notice, the Bureau of Justice
Statistics received no comments on the
proposed collection.
DATES: Comments are encouraged and
will be accepted for 30 days until March
25, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Connor Brooks, Statistician, Law
Enforcement Statistics Unit, Bureau of
Justice Statistics, 810 Seventh Street
NW, Washington, DC 20531 (email:
Connor.Brooks@usdoj.gov; phone: 202–
514–8633). Written comments and/or
suggestions can also be sent to the
Office of Management and Budget,
Office of Information and Regulatory
Affairs, Attention Department of Justice
Desk Officer, Washington, DC 20503 or
sent to OIRA_submissions@
omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
SUMMARY:
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
5501
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Reinstatement of the Census of Medical
Examiner and Coroner Offices, with
changes, of a previously approved
collection for which approval has
expired.
(2) The Title of the Form/Collection:
2018 Census of Medical Examiner and
Coroner Offices.
(3) The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form number is CMEC–1. The
applicable component within the
Department of Justice is the Bureau of
Justice Statistics, Office of Justice
Programs.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
This information collection is a
census of medical examiner and coroner
offices. The 2018 survey is revised from
the data collection referencing 2004.
Respondents will be the medical
examiners and coroners (or members of
their staff) working in medicolegal death
investigation offices.
Abstract: The 2018 CMEC will focus
on the same topics as the 2004: The
number and type of medical examiner
and coroner offices operating in the
U.S., staff at these offices, budget and
capital resources, workload, policies
and procedures regarding casework,
specialized death investigations, records
and evidence retention, resources, and
operations. The survey was assessed by
a panel of practitioners and subject
matter experts. Results from these
efforts were used to revise the survey to
ensure content was up-to-date and
relevant to the medicolegal death
investigation system today. The survey
was also revised to improve clarity and
ease of answering questions.
Suggestions resulting from this review
were incorporated into the survey and
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 84, Number 35 (Thursday, February 21, 2019)]
[Notices]
[Page 5501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02881]
[[Page 5501]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Research
Triangle Institute
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before March 25, 2019. Such
persons may also file a written request for a hearing on the
application on or before March 25, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
25, 2018, Research Triangle Institute, 3040 East Cornwallis Road,
Hermann Bldg., Room 106, Research Triangle Park, North Carolina 27709,
re-applied to be registered as a bulk manufacturer of small quantities
of Tetrahydrocannabinols (7370), a basic class of a controlled
substance listed in schedule I.
The company will manufacture via synthesis Tetrahydrocannabinols
(7370), for use by researchers as Active Pharmaceutical Ingredients
(API) for clinical trials.
Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-02881 Filed 2-20-19; 8:45 am]
BILLING CODE 4410-09-P
